Postoperative radiotherapy in prostate cancer: Analysis of prognostic factors in a series of 282 patients

Abstract Aim To assess the outcomes of patients treated with postoperative RT in relation to the possible prognostic factors. Background Postoperative radiotherapy (RT) has been proved to reduce the risk of biochemical recurrence in high-risk prostate cancer patients. Baseline prostate specific anti...

Full description

Saved in:
Bibliographic Details
Published in:Reports of practical oncology and radiotherapy 2015-03, Vol.20 (2), p.113-122
Main Authors: Apicella, Giuseppina, Beldì, Debora, Marchioro, Giansilvio, Torrente, Sara, Tunesi, Sara, Magnani, Corrado, Volpe, Alessandro, Terrone, Carlo, Krengli, Marco
Format: Article
Language:English
Subjects:
Biochemical recurrence
Hematology, Oncology and Palliative Medicine
Original
Postoperative radiotherapy
Prostate cancer
Radiology
Salvage radiotherapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Aim To assess the outcomes of patients treated with postoperative RT in relation to the possible prognostic factors. Background Postoperative radiotherapy (RT) has been proved to reduce the risk of biochemical recurrence in high-risk prostate cancer patients. Baseline prostate specific antigen (PSA), pathological Gleason score (GS), positive surgical margins, nodal status and seminal vesicle invasion are independent predictors of biochemical relapse. Materials and methods The clinical records of 282 patients who underwent postoperative RT were retrospectively reviewed. The prognostic value of postoperative PSA, preoperative risk class, nodal status, pathological GS, margins status, and administration of hormonal therapy (HT) was analyzed. Results Postoperative RT was delivered with a median dose to the prostatic fossa of 66 Gy (range 50–72) in 1.8–2 Gy/fraction. Median follow-up was 23.1 months (range 6–119). Five-year actuarial biochemical disease-free survival (bDFS) and overall survival rates were 76% and 95%, respectively. Higher bDFS was found for patients with postoperative PSA 0.02 ng/ml could be considered as a prognostic factor and a tool to select patients at risk for progression.
ISSN:1507-1367
2083-4640
DOI:10.1016/j.rpor.2014.10.001